The Finlay Institute of Vaccines of Cuba has announced the registration of a new clinical trial of vaccine candidate Soberana 01.

Havana, October 18 (RHC)-- The Finlay Institute of Vaccines of Cuba has announced the registration of a new clinical trial in the public registry to evaluate different formulations and dose schemes of the nationally produced drug against COVID-19 -- Soberana 01.

As explained by the institution on its official Twitter account: "The studies carried out so far have shown the safety of the Cuban vaccine and the best will advance to higher phases of clinical trials."

This second project against COVED-19 -- called Soberana 01 A -- will be carried out in parallel to the first trial registered by Finlay, which seeks to evaluate safety and reactogenicity.

Incorporated to the public registry of the regulatory authority of the Center for the State Control of Medicines, Equipment and Medical Devices (Cecmed), another objective of the new research is to explore the immunogenicity of different formulations of the vaccine candidates FINLAY FR-1 and FINLAY FR-1A in different schemes.

Recently, the director of the Finlay Institute of Vaccines, Vicente Vérez, advanced that this project is different, with the same antigen, but with another platform.